Compare GXO Logistics Inc (GXO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Merck & Co., Inc. — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 66× GXO Logistics Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Merck & Co., Inc. for 98 Days on average.
| GXO | MRK | |
|---|---|---|
Market Cap | $5.32B | $351.28B |
Volume | 1,255,816 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $65.59 | $156.43 |
52-Week Low | $44.17 | $82.49 |
Typical Hold Time | 28 Days | 98 Days |
Enterprise Value | $10.67B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.36, up 0.8% with neutral technical indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and strong analyst support (88.9% buy ratings). Recent strategic partnerships with Columbia Sportswear and aerospace/defense expansion signal growth potential, though margins remain thin with net income at 0.96%.
GXO presents a compelling growth story with 42% upside to consensus price target of $66.67. Key catalysts include logistics industry recovery and operational efficiency initiatives, but investors face margin pressure risks and competitive threats in the contract logistics space that could limit profitability expansion.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
